Loading
RNA, Ribosomal, 16S / Artificial Intelligence / Irritable Bowel Syndrome · Journal article
Gut Microbes · August 20, 2026
Encouraging direction, but not yet definitive.
This 12-month follow-up of a multicenter open-label RCT with blinded outcome assessment reports that a microbiome-guided personalized diet maintained IBS symptom improvement and gut microbiota diversity gains over 12 months, whereas a standard low-FODMAP diet's benefits regressed by the 12-month mark. The personalized diet group showed higher responder rates (62.5% vs 34.5%) and more favourable trajectories on quality of life and mood measures, but the authors frame these findings as hypothesis-generating and explicitly call for larger confirmatory trials.
Multicenter, parallel-group, randomized controlled trial with open-label intervention and blinded outcome assessment (PROBE design); 12-month follow-up. Adults aged 18–65 years meeting Rome IV criteria for IBS, recruited from four gastroenterology outpatient clinics in Istanbul, Izmir, and Kayseri, Turkey. Study conducted August 2022 to May 2023.. Intervention: Microbiome-guided personalized diet integrating microbiome profiling and artificial intelligence algorithms to tailor dietary recommendations to individual gut microbial profile. Compared with: Standardized low-FODMAP diet. Four gastroenterology outpatient clinics in Istanbul, Izmir, and Kayseri, Turkey.
Personalized diet maintained IBS-SSS improvement at 12 months (−78.3 points from baseline) while low-FODMAP diet benefits regressed (+29.3 points; between-group p = 0.001) IBS-SSS responder rates at 12 months: personalized diet 62.5% vs low-FODMAP 34.5% (absolute risk difference +28.0%, 95% CI 4.2–47.7; Fisher p = 0.029) Personalized diet sustained Shannon alpha-diversity gains (+0.205 at 12 months; p ≤ 0.01)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should note that this trial suggests a microbiome-guided personalized diet may sustain IBS symptom relief over 12 months better than the low-FODMAP diet, which may lose efficacy post-intervention. However, the authors explicitly frame findings as hypothesis-generating; practitioners should await larger confirmatory trials before changing standard IBS management protocols based on these results alone.
A 12-month follow-up RCT with blinded outcome assessment comparing two dietary interventions in IBS, showing sustained clinical benefit with personalized diet but requiring larger trials to confirm durability and microbiome mechanisms.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should note that this trial suggests a microbiome-guided personalized diet may sustain IBS symptom relief over 12 months better than the low-FODMAP diet, which may lose efficacy post-intervention. However, the authors explicitly frame findings as hypothesis-generating; practitioners should await larger confirmatory trials before changing standard IBS management protocols based on these results alone.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Dietary therapy is central to irritable bowel syndrome (IBS) management, yet the long-term durability of the low-FODMAP diet (LFD), and of microbiome-guided personalization, remains unclear. We assessed the long-term clinical and gut-microbiome effects of a microbiome-guided personalized diet (PD) compared with a standard LFD in adults meeting Rome IV criteria for IBS. In this multicenter, open-label randomized controlled trial with blinded outcome assessment, participants who completed a 6-week dietary intervention (PD or LFD) were followed at 6 and 12 months without further dietary intervention. Outcomes included the IBS Severity Scoring System (IBS-SSS), IBS Quality of Life (IBS-QOL), and the Hospital Anxiety and Depression Scale (HADS); gut microbiota were profiled by 16S rRNA sequencing. Longitudinal changes were evaluated using linear mixed-effects models, responder analyses, PERMANOVA, and PERMDISP. Both diets reduced IBS-SSS at 6 weeks. PD maintained symptom improvement at 6 and 12 months (-82.0 and -78.3 points from baseline), whereas LFD benefits regressed by 12 months (+29.3 points; between-group p = 0.001). At 12 months, IBS-SSS responder rates were higher with PD than LFD (62.5% vs 34.5%; absolute risk difference +28.0%, 95% CI 4.2-47.7; Fisher p = 0.029), and IBS-QOL, HADS-anxiety, and HADS-depression showed more favourable trajectories with PD. PD was associated with sustained Shannon alpha-diversity gains (+0.488 at 6 weeks; +0.205 at 12 months; both p < 0.01). A modest between-group beta-diversity difference at 6 months (R2 = 0.035; p = 0.011) was not significant at 12 months. This hypothesis-generating follow-up suggests more durable benefit with PD; larger trials powered for long-term clinical and microbiome outcomes are warranted.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.